JG
ICPT

Joel Greenblatt’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Joel Greenblatt’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,567
Closed -$566K – 1243
2019
Q4 		$566K Buy
+4,567
New +$409K 0.01% 773
2019
Q2 		– Sell
-2,760
Closed -$309K – 1323
2019
Q1 		$309K Buy
+2,760
New +$302K ﹤0.01% 989

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Joel Greenblatt's ICPT Position: Q1 2020 in Review

Joel Greenblatt sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 4,567 shares — an estimated $566K sold.

Joel Greenblatt first reported a position in ICPT in Q1 2019 and held it in 2 quarters. The position peaked at $566K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Joel Greenblatt reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Joel Greenblatt sold 4,567 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $566K.
  • Joel Greenblatt first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Joel Greenblatt's Intercept Pharmaceuticals, Inc. position peaked at $566K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Gotham Asset Management's 13F filing for Q1 2020, filed 15 May 2020.